At week 68, 78.8% of children receiving semaglutide improved by at least 1 BMI category compared with 23.4% receiving placebo (OR, 7.8; 95% CI, 3.5-17.6; P < .001).
Additionally, 38.4% of children receiving semaglutide were no longer classified as having obesity, defined as a BMI below the 95th percentile for age and sex, compared with 2.1% receiving placebo.
Treating obesity with semaglutide was accompanied by improvements in multiple cardiometabolic measures, suggesting that effective treatments for severe childhood obesity may shift a child’s trajectory back towards one of improving weight related health.
In the efficacy analysis, 83.0% of semaglutide recipients improved their BMI category, while 40.4% had a BMI below the obesity threshold. Corresponding proportions in the placebo group were 23.5% and 0%, respectively.²
Nearly 79% of children receiving semaglutide in the efficacy analysis achieved a BMI reduction of at least 10%, compared with no placebo recipients. In the observed treatment-regimen analysis, the corresponding proportions were 74.7% and 4.3%.
Were BMI Improvements Maintained Through 104 Weeks?
Semaglutide-associated BMI reductions persisted through 104 weeks, although the magnitude of reduction was smaller than at the primary 68-week assessment.
At week 104, mean BMI had decreased by 9.4% from baseline among children receiving semaglutide, compared with an 8.4% increase among placebo recipients, representing a between-group difference of −17.8 percentage points (95% CI, −22.2 to −13.3).¹
In the efficacy analysis, mean BMI decreased by 14.0% with semaglutide compared with a 5.7% increase with placebo.
At week 104, 77.1% of children receiving semaglutide had improved their BMI category compared with 24.4% receiving placebo. Approximately one-third (33.3%) of semaglutide recipients were no longer classified as having obesity, compared with 2.4% of placebo recipients.²
However, Novo Nordisk noted that week 104 secondary endpoint analyses were not adjusted for multiple comparisons and should be interpreted as supportive rather than definitive evidence of treatment effects.
What Were the Safety Findings in STEP Young?
The overall safety profile of semaglutide was consistent with previous clinical trials involving adolescents and adults, according to the investigators.
Adverse events occurred in 96% of children receiving semaglutide and 93% receiving placebo. Gastrointestinal adverse events were the most frequently reported and occurred more often with semaglutide.¹
Gastrointestinal adverse events led to treatment discontinuation in 1 child receiving semaglutide.
Novo Nordisk reported that no unexpected safety signals were identified, including no identified safety concerns related to growth or pubertal development during the trial.²
However, the long-term effects of semaglutide treatment initiated in childhood, particularly regarding growth, development, and sustained weight management, require continued investigation.
Semaglutide also carries a boxed warning concerning thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
What Do the Findings Mean for Pediatric Obesity Management in Primary Care?
The STEP Young findings may be particularly relevant for primary care physicians and pediatricians managing children with severe obesity who have limited options for pharmacologic treatment.
Childhood obesity is associated with increased risks of type 2 diabetes, dyslipidemia, hypertension, obstructive sleep apnea, and other cardiometabolic complications that can persist into adulthood.
The trial provides evidence that semaglutide, when combined with lifestyle modification, can produce substantial BMI reductions and improve obesity classification in children younger than 12 years.
However, the results do not establish the long-term effects of treatment on cardiovascular outcomes, diabetes incidence, or other obesity-related complications.
The relatively small sample size and limited follow-up beyond treatment discontinuation also leave questions regarding long-term safety, treatment duration, and weight regain after stopping therapy.
For primary care physicians, the findings reinforce the importance of early identification and comprehensive management of childhood obesity, including family-centered behavioral interventions, nutritional counseling, physical activity support, and assessment for obesity-related complications.
Semaglutide is currently FDA approved for chronic weight management in adolescents aged 12 years and older and adults, but is not approved in the US for children younger than 12 years. Its use in this younger population remains investigational.
The investigators concluded that once-weekly semaglutide significantly reduced BMI and improved obesity classification compared with placebo among children aged 6 to younger than 12 years, supporting continued investigation of GLP-1 receptor agonist treatment for severe childhood obesity.
References
- Jastreboff AM, Harder-Lauridsen NM, Van Name M, et al. Semaglutide for the treatment of obesity in children 6 to younger than 12 years of age. N Engl J Med. Published online November 16, 2026. doi:10.1056/NEJMoa2604058.
- Novo Nordisk. Wegovy resulted in a BMI reduction of 10% or more in almost 80% of children with obesity aged 6 to under 12, compared to 0% with placebo in STEP Young trial, published in The New England Journal of Medicine. News release. November 16, 2026.
- ClinicalTrials.gov. Semaglutide in children with obesity (STEP Young). NCT05726227.